3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
47
Lung Neoplasms
23
Carcinoma, Hepatocellular
23
Small Cell Lung Carcinoma
16
Cholangiocarcinoma
10
Breast Neoplasms
10
Urinary Bladder Neoplasms
9
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Liver Neoplasms
8
Pancreatic Neoplasms
6
Carcinoma
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Interventions
ruxolitinib
9
fludarabine phosphate
8
fludarabine
8
Whole-Body Irradiation
8
Specimen Handling
7
Cytarabine
7
Cyclophosphamide
7
Mycophenolic Acid
6
Tacrolimus
5
Injections
5
Busulfan
5
Biopsy
5
Azacitidine
5
Stem Cell Transplantation
4
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
CPX-351
4
venetoclax
3
luspatercept
3
decitabine and cedazuridine drug combination
3
Liposomes
3
Idarubicin
3
Daunorubicin
3
Cyclosporine
3
Blood Specimen Collection
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
selinexor
2
nilotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
durvalumab
×
90 days
×
Clear all
No trials found.